RoslinCT and Ayrmid Pharma plan to enter into a strategic partnership for the production of Omisirge®, a treatment for hematologic malignancies commercialized in the United States by Gamida Cell, a subsidiary of Ayrmid Pharma.
Officials from both companies say it is their intent to sign an agreement whereby RoslinCT will perform technology transfer and commercial manufacture of Gamida Cells’s Omisirge. The cell-based product is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy that was FDA-approved and launched in 2023. The goal is to have technology transfer and commercial manufacturing take place in RoslinCT’s purpose-built cell therapy CGMP manufacturing facility in Hopkinton, MA.
“This key strategic move will allow Gamida Cell to source Omisirge for our patients from both our internal manufacturing capability and RoslinCT,” said Joseph Wiley, CEO of Ayrmid.
“The dynamic interactions between the two teams are productive and we look forward to working with the Ayrmid Pharma and Gamida Cell teams to support the production of this innovative product for their patients in the U.S.,” added Peter Coleman, CEO of RoslinCT.
RoslinCT, a CDMO focused on advanced cell and gene therapies, was established in 2006 and built upon the technology that cloned Dolly the Sheep at the Roslin Institute in 1997. In collaboration with Vertex Pharmaceuticals, RoslinCT developed, from early process development through commercialization, the first CRISPR-edited cell therapy product (exa-cel) for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia.